Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ihor Arkhypov

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The Journal of Clinical Investigation|July 3, 2023
Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic targetFeyza Gul Ozbay Kurt, Samantha Lasser, Ihor Arkhypov, et al.
Nature Reviews. Clinical Oncology|January 9, 2024
Myeloid-derived suppressor cells in cancer and cancer therapySamantha A Lasser, Feyza G Ozbay Kurt, Ihor Arkhypov, et al.
International Journal of Molecular Sciences|April 3, 2020
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in MelanomaVera Petrova, Ihor Arkhypov, Rebekka Weber, et al.
Cellular Immunology|December 9, 2020
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapyRebekka Weber, Christopher Groth, Samantha Lasser, et al.
Oncoimmunology|August 18, 2023
Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCsAlisa Lepper, Rebekka Bitsch, Feyza Gül Özbay Kurt, et al.
International Journal of Molecular Sciences|September 4, 2020
Myeloid Cell Modulation by Tumor-Derived Extracellular VesiclesIhor Arkhypov, Samantha Lasser, Vera Petrova, et al.
Frontiers in Immunology|March 2, 2023
Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patientsVera Petrova, Christopher Groth, Rebekka Bitsch, et al.
Cancers|December 17, 2020
HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in MelanomaLaura Hüser, Marianthi-Maria Kokkaleniou, Karol Granados, et al.
Frontiers in Immunology|October 31, 2022
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2Feyza Gül Özbay Kurt, Alisa Lepper, Catharina Gerhards, et al.
Journal for Immunotherapy of Cancer|September 16, 2022
HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signalingIhor Arkhypov, Feyza Gül Özbay Kurt, Rebekka Bitsch, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The Journal of Clinical Investigation|July 3, 2023
Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic targetFeyza Gul Ozbay Kurt, Samantha Lasser, Ihor Arkhypov, et al.
Nature Reviews. Clinical Oncology|January 9, 2024
Myeloid-derived suppressor cells in cancer and cancer therapySamantha A Lasser, Feyza G Ozbay Kurt, Ihor Arkhypov, et al.
International Journal of Molecular Sciences|April 3, 2020
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in MelanomaVera Petrova, Ihor Arkhypov, Rebekka Weber, et al.
Cellular Immunology|December 9, 2020
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapyRebekka Weber, Christopher Groth, Samantha Lasser, et al.
Oncoimmunology|August 18, 2023
Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCsAlisa Lepper, Rebekka Bitsch, Feyza Gül Özbay Kurt, et al.
International Journal of Molecular Sciences|September 4, 2020
Myeloid Cell Modulation by Tumor-Derived Extracellular VesiclesIhor Arkhypov, Samantha Lasser, Vera Petrova, et al.
Frontiers in Immunology|March 2, 2023
Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patientsVera Petrova, Christopher Groth, Rebekka Bitsch, et al.
Cancers|December 17, 2020
HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in MelanomaLaura Hüser, Marianthi-Maria Kokkaleniou, Karol Granados, et al.
Frontiers in Immunology|October 31, 2022
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2Feyza Gül Özbay Kurt, Alisa Lepper, Catharina Gerhards, et al.
Journal for Immunotherapy of Cancer|September 16, 2022
HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signalingIhor Arkhypov, Feyza Gül Özbay Kurt, Rebekka Bitsch, et al.
Pageof 2